Mavenclad (cladribine) - Important Safety Information from Merck Serono (Ireland) Limited as approved by the HPRA (14.02.22)

Notice type: 3rd Party Publications

Date: 16/02/2022




Problem Or Issue:

Important Safety Information from Merck Serono (Ireland) Limited regarding Mavenclad (cladribine) –  risk of serious liver injury and new recommendations about liver function monitoring


Important Safety Information ­–  Mavenclad (cladribine)  


« Back